Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.

POINT Biopharma Global (PNT) News Today

POINT Biopharma Global logo
Lilly Completes Acquisition of POINT Biopharma
POINT Biopharma Global Inc. stock logo
POINT Biopharma Global (NASDAQ:PNT) Receives Hold Rating from Brookline Capital Management
Brookline Capital Management reissued a "hold" rating and set a $12.50 price objective (down previously from $27.00) on shares of POINT Biopharma Global in a research note on Thursday.
POINT Biopharma Global Inc. stock logo
POINT Biopharma Global Sees Unusually High Options Volume (NASDAQ:PNT)
POINT Biopharma Global Inc. (NASDAQ:PNT - Get Free Report) saw unusually large options trading on Monday. Stock traders bought 20,626 call options on the company. This is an increase of approximately 162% compared to the average volume of 7,869 call options.
POINT Biopharma Global Inc. stock logo
POINT Biopharma Global Inc. (NASDAQ:PNT) Short Interest Down 28.1% in November
POINT Biopharma Global Inc. (NASDAQ:PNT - Get Free Report) was the recipient of a large decrease in short interest in November. As of November 30th, there was short interest totalling 2,640,000 shares, a decrease of 28.1% from the November 15th total of 3,670,000 shares. Based on an average trading volume of 2,740,000 shares, the short-interest ratio is currently 1.0 days. Approximately 3.0% of the shares of the company are short sold.
POINT Biopharma Global Inc. stock logo
Stock Traders Buy Large Volume of Put Options on POINT Biopharma Global (NASDAQ:PNT)
POINT Biopharma Global Inc. (NASDAQ:PNT - Get Free Report) was the target of unusually large options trading activity on Wednesday. Traders bought 11,904 put options on the company. This is an increase of approximately 73% compared to the average daily volume of 6,892 put options.
Piper Sandler Keeps Their Hold Rating on POINT Biopharma Global (PNT)
Recap: POINT Biopharma Global Q3 Earnings
Lilly Extends Tender Offer For POINT Biopharma Global Until Nov. 16
Crude Oil Moves Higher; POINT Biopharma Global Shares Jump
Eli Lilly POINTs Toward Radiopharmaceutical Ambitions
Eli Lilly to acquire Point Biopharma in $1.4B deal
Remove Ads
Get POINT Biopharma Global News Delivered to You Automatically

Sign up to receive the latest news and ratings for PNT and its competitors with MarketBeat's FREE daily newsletter.

PNT Media Mentions By Week

PNT Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

PNT
News Sentiment

0.00

0.76

Average
Medical
News Sentiment

PNT News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

PNT Articles
This Week

0

0

PNT Articles
Average Week

Remove Ads
Get POINT Biopharma Global News Delivered to You Automatically

Sign up to receive the latest news and ratings for PNT and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:PNT) was last updated on 3/15/2025 by MarketBeat.com Staff
From Our Partners